Group III mGlu receptor agonists produce anxiolytic- and antidepressant-like effects after central administration in rats

Neuropharmacology

Volumn 46, Issue 2, 2004, Pages 151-159

  Palucha A ^a   Tatarczynska E ^a   Branski P ^a   Szewczyk, B ^a   Wieronska J M ^a   Klak K ^a   Chojnacka Wojcik E ^c   Nowak, G ^a,b   Pilc, A ^a,b  

^a INSTITUTE OF PHARMACOLOGY   (Poland)

^b JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

^c NONE

Author keywords

ACPT I; Anxiety; Conflict drinking test; CPPG; Depression; Forced swimming test; Group III mGlu receptors; HomoAMPA; RS PPG

Indexed keywords

1 AMINOCYCLOPENTANE 1,3,4 TRICARBOXYLIC ACID; 2 AMINO 4 (3 HYDROXY 5 METHYLISOXAZOL 4 YL)BUTYRIC ACID; ALPHA CYCLOPROPYL 4 PHOSPHONOPHENYLGLYCINE; GLUTAMATE RECEPTOR AGONIST; GLUTAMATE RECEPTOR ANTAGONIST; UNCLASSIFIED DRUG;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONFLICT; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DRINKING; DRUG EFFICACY; FORCED SWIMMING TEST; LOCOMOTION; MALE; NEUROTRANSMITTER RELEASE; NONHUMAN; PRIORITY JOURNAL; RAT; RECEPTOR INTRINSIC ACTIVITY; TASK PERFORMANCE; TRANQUILIZING ACTIVITY;

EID: 0346219343     PISSN: 00283908     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuropharm.2003.09.006     Document Type: Article

References (44)

1. Acher F.C., Tellier F.J., Azerad R., Brabet I.N., Fagni L., Pin J.P. Synthesis and pharmacological characterization of aminocyclopentanetricarboxylic acids: new tools to discriminate between metabotropic glutamate receptor subtypes. Journal of Medical Chemistry. 40:1997;3119-3129.
2. Andrews G., Sanderson K., Slade T., Issakidis C. Why does the burden of disease persist? Relating the burden of anxiety and depression of effectiveness of treatment. Bulletin of World Health Organisation. 78:2000;446-454.
3. Baskys A., Malenka R.C. Agonists at metabotropic glutamate receptors presynaptically inhibit EPSCs in neonatal rat hippocampus. Journal of Physiology. 444:1991;687-701.
4. Boehm S. Presynaptic alpha2-adrenoceptors control excitatory, but not inhibitory, transmission at rat hippocampal synapses. Journal of Physiology. 519:1999;439-449.
5. Bradley S.R., Levey A.I., Hersch S.M., Conn P.J. Immunocytochemical localization of group III metabotropic glutamate receptors in the hippocampus with subtype-specific antibodies. Journal of Neuroscience. 16:1996;2044-2056.
6. Brauner-Osborne H., Slok F.A., Skjaerbaek N., Ebert B., Sekiyama N., Nakanishi S., Krogsgaard-Larsen P. A new highly selective metabotropic excitatory amino acid agonist: 2-amino-4-(3-hydroxy-5-methylisoxazol-4-yl) butyric acid. Journal of Medical Chemistry. 39:1996;3188-3194.
7. Conn P.J., Pin J.P. Pharmacology and functions of metabotropic glutamate receptors. Annual Review of Pharmacological Toxicology. 37:1997;205-237.
8. Chojnacka-Wójcik E., Tatarczyńska E., Pilc A. The anxiolytic-like effect of metabotropic glutamate receptor antagonists after intrahippocampal injection in rats. European Journal of Pharmacology. 319:1997;153-156.
9. Chojnacka-Wójcik E., Klodzińska A., Pilc A. Glutamate receptor ligands as anxiolytics. Current Opinion in Investigational Drugs. 2:2001;1112-1119.
10. Cosford N.D., Tehrani L., Roppe J., Schweiger E., Smith N.D., Anderson J., Bristow L., Brodkin J., Jiang X., McDonald I., Rao S., Washburn M., Varney M.A. 3-[(2-Methyl-1,3-thiazol-4-yl)ethynyl]-pyridine: a potent and highly selective metabotropic glutamate subtype 5 receptor antagonist with anxiolytic activity. Journal of Medical Chemistry. 46:2003;204-206.
11. Danysz W., Parsons C.G., Bresnick I., Quack G. Glutamate in CNS disorders. Drugs News Perspectives. 8:1996;261-277.
12. Gasparini F., Bruno V., Battaglia G., Lukic S., Leonhardt T., Inderbitzin W., Laurie D., Sommer B., Varney M.A., Hess S.D., Johnson E.C., Kuhn R., Urwyler S., Sauer D., Portet C., Schmutz M., Nicoletti F., Flor P.J. (R,S)-4-phosphonophenylglycine, a potent and selective group III metabotropic glutamate receptor agonist, is anticonvulsive and neuroprotective in vivo. Journal of Pharmacology and Experimental Therapeutics. 289:1999;1678-1687.
13. Gereau R.W., Conn P.J. Multiple presynaptic metabotropic glutamate receptors modulate excitatory and inhibitory synaptic transmission in hippocampal area CA1. Journal of Neuroscience. 15:1995;6879-6889.
14. Golembiowska K., Dziubina A. Effect of acute and chronic administration of citalopram on glutamate and aspartate release in the rat prefrontal cortex. Polish Journal of Pharmacology. 52:2000;441-448.
15. Golembiowska K., Dziubina A. Involvement of adenosine in the effect of antidepressants on glutamate and aspartate release in the rat prefrontal cortex. Naunyn Schmiedeberg's Archives of Pharmacology. 363:2001;663-670.
16. Gray J.A. Precis of the neuropsychology of anxiety: an enquiry into the functions of the septo-hippocampal system. Behavioral Brain Science. 5:1982;469-534.
17. Helton D.R., Tizzano J.P., Monn J.A., Schoepp D.D., Kallman M.J. Anxiolytic and side-effect profile of LY354740: a potent, highly selective, orally active agonist for group II metabotropic glutamate receptors. Journal of Pharmacology and Experimental Therapeutics. 284:1998;651-660.
18. Jin X., Daw N.W. The group III metabotropic glutamate receptor agonist, L-AP4, reduces EPSPs in some layers of rat visual cortex. Brain Research. 797:1998;218-224.
19. Klodzińska A., Chojnacka-Wójcik E., Palucha A., Brański P., Popik P., Pilc A. Potential anti-anxiety, anti-addictive effects of LY 354740, a selective group II glutamate metabotropic receptors agonist in animal models. Neuropharmacology. 38:1999;1831-1839.
20. Koerner J.F., Cotman C.W. Micromolar L-2-amino-4-phosphonobutyric acid selectively inhibits perforant path synapses from lateral enthorinal cortex. Brain Research. 216:1981;192-198.
21. Michael-Titus A.T., Bains S., Jeetle J., Whelpton R. Imipramine and phenelzine decrease glutamate overflow in the prefrontal cortex - a possible mechanism of neuroprotection in major depression? Neuroscience. 100:2000;681-684.
22. Michaud C.M., Murray C.J., Bloom B.R. Burden of disease - implications for future research. The Journal of the American Medical Association. 285:2001;535-539.
23. Nakanishi S. Molecular diversity of glutamate receptors and implications for brain function. Science. 258:1992;597-603.
24. Palucha A., Pilc A. On the role of metabotropic glutamate receptors in the mechanism of action of antidepressants. Polish Journal of Pharmacology. 54:2002;581-586.
25. Paul I.A. Excitatory amino acid signaling, major depression and the action of antidepressants. Pharmaceutical News. 3:2001;25-36.
26. Paxinos G., Watson C. The Rat Brain in Stereotaxic Coordinates. 1986;Academic, Sydney.
27. Pilc A., Klodzińska A., Brański P., Nowak G., Palucha A., Szewczyk B., Tatarczyńska E., Chojnacka-Wójcik E., Wierońska J.M. Multiple MPEP administrations evoke anxiolytic- and antidepressant-like effects in rats. Neuropharmacology. 43:2002a;181-187.
28. Pilc A., Klodzińska A., Nowak G. A role of glutamate in the treatment of anxiety and depression. Focus on group I metabotropic glutamate (mGlu) receptors. Drugs of the Future. 27:2002b;1-11.
29. Porsolt R.D., Anton G., Blavet N., Jalfre M. Behavioural despair in rats: a new model sensitive to antidepressant treatments. European Journal of Pharmacology. 47:1978;379-391.
30. Prikhozhan A.V., Kovalev G.I., Raevskii K.S. Effects of antidepressive agents on glutamatergic autoregulatory presynaptic mechanism in the rat cerebral cortex. Bulletin of Experimental Biology and Medicine. 110:1990;624-626.
31. Rickels K., Rynn M. Pharmacotherapy of generalized anxiety disorder. Journal of Clinical Psychiatry. 63:2002;9-16.
32. Scanziani M., Gahwiler B.H., Thompson S.M. Presynaptic inhibition of excitatory synaptic transmission mediated by alpha adrenergic receptors in area CA3 of the rat hippocampus in vitro. Journal of Neuroscience. 13:1993;5393-5401.
33. Schmitz D., Gloveli T., Empson R.M., Draguhn A., Heinemann U. Serotonin reduces synaptic excitation in the superficial medial enthorinal cortex of the rat via a presynaptic mechanism. Journal of Physiology. 508:1998;119-129.
34. Schoepp D.D. Unveiling the functions of presynaptic metabotropic glutamate receptors in the central nervous system. Journal of Pharmacology and Experimental Therapeutics. 299:2001;12-20.
35. Shigemoto R., Kinoshita A., Wada E., Nomura S., Ohishi H., Takada M., Flor P.J., Neki A., Abe T., Nakanishi S., Mizuno N. Differential presynaptic localization of metabotropic glutamate receptor subtypes in the rat hippocampus. Journal of Neuroscience. 17:1997;7503-7522.
36. Skolnick P. Antidepressants for the new millennium. European Journal of Pharmacology. 375:1999;31-40.
37. Spooren W.P.J.M., Vassout A., Neijt H.C., Kuhn R., Gasparini F., Roux S., Porsolt R.D., Gentsch C. Anxiolytic-like effects of the prototypical metabotropic glutamate receptor 5 antagonist 2-methyl-6-(phenylethynyl)pyridine in rodents. Journal of Pharmacology and Experimental Therapeutics. 295:2000;1267-1275.
38. Tatarczyńska E., Klodzińska A., Chojnacka-Wójcik E., Palucha A., Gasparini F., Kuhn R., Pilc A. Potential anxiolytic- and antidepressant-like effects of MPEP, a potent, selective and systemically active mGlu5 receptor antagonist. British Journal of Pharmacology. 132:2001a;1423-1430.
39. Tatarczyńska E., Klodzińska A., Kroczka B., Chojnacka-Wójcik E., Pilc A. The antianxiety-like effects of antagonists of group I and agonists of group II and III metabotropic glutamate receptors after intrahippocampal administration. Psychopharmacology (Berlin). 158:2001b;94-99.
40. Tatarczyńska E., Palucha A., Szewczyk B., Chojnacka-Wójcik E., Wierońska J.M., Pilc A. Anxiolytic- and antidepressant-like effects of group III metabotropic glutamate agonist 1S, 3R, 4S-1-aminocyclo-pentane-1 tricarboxylic acid (ACPT-I) in rats. Polish Journal of Pharmacology. 54:2002;707-710.
41. Toms N.J., Jane D.E., Kemp M.C., Bedingfield J.S., Roberts P.J. The effects of (RS)-alpha-cyclopropyl-4-phosphonophenylglycine ((RS)-CPPG), a potent and selective metabotropic glutamate receptor antagonist. British Journal of Pharmacology. 119:1996;851-854.
42. Vogel J.R., Beer B., Clody D.E. A simple and reliable conflict procedure for testing anti-anxiety agents. Psychopharmacologia (Berlin). 21:1971;1-7.
43. Wróblewski J.T., Danysz W. Modulation of glutamate receptors: molecular mechanisms and functional implications. Annual Review of Pharmacology and Toxicology. 29:1989;441-474.
44. Zimmerman M., McDermut W., Mattia J.I. Frequency of anxiety disorders in psychiatric outpatients with major depressive disorder. American Journal of Psychiatry. 157:2000;1337-1340.